Abstract:Summary Background Recent studies have reported the predictive and prognostic value of novel transcriptional factor-based molecular subtypes in small-cell lung cancer (SCLC). We conducted an in-depth analysis pairing multi-omics data with immunohistochemistry (IHC) to elucidate the underlying characteristics associated with differences in clinical outcomes between subtypes. Methods IHC (n = 252), target exome sequencing (n = 422), and whole transcriptome sequencing (WTS, n = 189) data generated from 427 patients (86.4% males, 13.6% females) with SCLC were comprehensively analysed. The differences in the mutation profile, gene expression profile, and inflammed signatures were analysed according to the IHC-based molecular subtype. Findings IHC-based molecular subtyping, comprised of 90 limited-disease (35.7%) and 162 extensive-disease (64.3%), revealed a high incidence of ASCL1 subtype (IHC-A, 56.3%) followed by ASCL1/NEUROD1 co-expressed (IHC-AN, 17.9%), NEUROD1 (IHC-N, 12.3%), POU2F3 (IHC-P, 9.1%), triple-negative (IHC-TN, 4.4%) subtypes. IHC-based subtype showing high concordance with WTS-based subtyping and non-negative matrix factorization (NMF) clusterization method. IHC-AN subtype resembled IHC-A (rather than IHC-N) in terms of both gene expression profiles and clinical outcomes. Favourable median overall survival was observed in IHC-A (15.2 months) compared to IHC-N (8.0 months, adjusted HR 2.3, 95% CI 1.4–3.9, p = 0.002) and IHC-P (8.3 months, adjusted HR 1.7, 95% CI 0.9–3.2, p = 0.076). Inflamed tumours made up 25% of cases (including 53% of IHC-P, 26% of IHC-A, 17% of IHC-AN, but only 11% of IHC-N). Consistent with recent findings, inflamed tumours were more likely to benefit from first-line immunotherapy treatment than non-inflamed phenotype (p = 0.002). Interpretation This study provides fundamental data, including the incidence and basic demographics of molecular subtypes of SCLC using both IHC and WTS from a comparably large, real-world Asian/non-Western patient cohort, showing high concordance with the previous NMF-based SCLC model. In addition, we revealed underlying biological pathway activities, immunogenicity, and treatment outcomes based on molecular subtype, possibly related to the difference in clinical outcomes, including immunotherapy response. Funding This work was supported by AstraZeneca , Future Medicine 2030 Project of the Samsung Medical Center [grant number SMX1240011 ], the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) [grant number 2020R1C1C1010626 ] and the 7th AstraZeneca-KHIDI (Korea Health Industry Development Institute) oncology research program.

Proteomic Stratification of Prognosis and Treatment Options for Small Cell Lung Cancer

Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1.

Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma from Chinese Patients.

Prognostic Implications of Molecular Subtypes in Primary Small Cell Lung Cancer and Their Correlation With Cancer Immunity

Multi-dimensional characterization of immunological profiles in small cell lung cancer uncovers clinically relevant immune subtypes with distinct prognoses and therapeutic vulnerabilities

Molecular Subtyping of Small-Cell Lung Cancer Based on Mutational Signatures with Different Genomic Features and Therapeutic Strategies

Molecular classification of small cell lung cancer subtypes: Characteristics, prognostic factors, and clinical translation

Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer

Prognostic Biomarkers and Immune Cell Infiltration Characteristics in Small Cell Lung Cancer

Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study

Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies

Heterogeneity of molecular subtyping and therapy-related marker expression in primary tumors and paired lymph node metastases of small cell lung cancer

In‐depth proteomic analysis reveals unique subtype‐specific signatures in human small‐cell lung cancer

Advances in novel molecular typing and precise treatment strategies for small cell lung cancer

Integrative multi‐omic and machine learning approach for prognostic stratification and therapeutic targeting in lung squamous cell carcinoma

Integrative Analysis of Multi-Omics Data Reveals the Heterogeneity and Signatures of Immune Therapy for Small Cell Lung Cancer.

Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer

Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy

Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies